Q06187 | SWISS-MODEL Repository

Q06187 (BTK_HUMAN) Homo sapiens (Human)

Tyrosine-protein kinase BTK UniProtKB InterPro STRING Interactive Modelling

It is possible new templates exist for this target since these models were created.

		521	Proton acceptor
		143	Zinc
		154	Zinc
		155	Zinc
		165	Zinc
		11	L -> P (in XLA) VAR_006216
		12	K -> R (in XLA) VAR_006217
		14	S -> F (in XLA) VAR_006218
		19	K -> E (in XLA) VAR_008291
		25	F -> S (in XLA) VAR_006219
		27	K -> R (in XLA) VAR_008292
		28	R -> C (in XLA; no effect on phosphorylation of GTF2I) VAR_008293
		28	R -> H (in XLA; moderate; dbSNP:rs128620185) VAR_006220 dbSNP
		28	R -> P (in XLA) VAR_006221
		33	T -> P (in XLA; severe; dbSNP:rs128620189) VAR_006222 dbSNP
		39	Y -> S (in XLA) VAR_008960
		40	Y -> C (in XLA; dbSNP:rs1555980875) VAR_008294 dbSNP
		40	Y -> N (in XLA) VAR_008295
		61	I -> N (in XLA) VAR_008296
		64	V -> D (in XLA) VAR_008297
		64	V -> F (in XLA) VAR_006223
		82	R -> K (in dbSNP:rs56035945) VAR_041676 dbSNP
		103	Q -> QSVFSSTR (in XLA) VAR_006224
		113	V -> D (in XLA; dbSNP:rs128621190) VAR_006225 dbSNP
		115	S -> F (in XLA) VAR_008298
		117	T -> P (in XLA) VAR_008299
		127	Q -> H (in XLA) VAR_008300
		154	C -> S (in XLA) VAR_008301
		155	C -> G (in XLA) VAR_008302
		155	C -> R (in XLA) VAR_008303
		184	T -> P (in XLA) VAR_008304
		190	P -> K (in a lung large cell carcinoma sample; somatic mutation; requires 2 nucleotide substitutions) VAR_041677
		288	R -> Q (in XLA; dbSNP:rs1555978277) VAR_008305 dbSNP
		288	R -> W (in XLA; dbSNP:rs128621194) VAR_006227 dbSNP
		295	L -> P (in XLA) VAR_006228
		302	G -> E (in XLA) VAR_006230
		302	G -> R (in XLA) VAR_008306
		302	Missing (in XLA) VAR_006229
		307	R -> G (in XLA; loss of activity; dbSNP:rs128621195) VAR_006231 dbSNP
		307	R -> T (in XLA) VAR_008307
		308	D -> E (in XLA) VAR_008308
		319	V -> A (in XLA; moderate) VAR_008309
		334	Y -> S (in XLA; dbSNP:rs128621196) VAR_006232 dbSNP
		358	L -> F (in XLA) VAR_006233
		361	Y -> C (in XLA; mild; dbSNP:rs28935478) VAR_006234 dbSNP
		362	H -> Q (in XLA) VAR_006235
		364	H -> P (in XLA) VAR_006236
		365	N -> Y (in XLA) VAR_006237
		366	S -> F (in XLA) VAR_008310
		369	L -> F (in XLA) VAR_008311
		370	I -> M (in XLA) VAR_006238
		372	R -> G (in XLA) VAR_008312
		408	L -> P (in XLA; moderate; dbSNP:rs128621198) VAR_006239 dbSNP
		414	G -> R (in XLA) VAR_008313
		418	Y -> H (in XLA; dbSNP:rs144079566) VAR_006240 dbSNP
		429	I -> N (in XLA) VAR_006241
		430	K -> E (in XLA; loss of phosphorylation of GTF2I; dbSNP:rs128620184) VAR_006242 dbSNP
		430	K -> R (in XLA) VAR_008314
		445	E -> D (in XLA) VAR_008315
		462	G -> D (in XLA) VAR_008316
		462	G -> V (in XLA) VAR_008317
		476	Y -> D (in XLA) VAR_006243
		477	M -> R (in XLA) VAR_006244
		481	C -> S (found in patients with chronic lymphocytic leukemia; unknown pathological significance; results in resistance to ibrutinib therapy; results in a protein that is reversibly inhibited by ibrutinib; disrupts the covalent binding between the enzyme and ibrutinib; dbSNP:rs1057519825 and dbSNP:rs1057519826) VAR_074309 dbSNP
		502	C -> F (in XLA) VAR_006245
		502	C -> W (in XLA; dbSNP:rs41310709) VAR_006246 dbSNP
		506	C -> R (in XLA; dbSNP:rs128621200) VAR_006247 dbSNP
		506	C -> Y (in XLA) VAR_006248
		508	A -> D (in XLA) VAR_008318
		509	M -> I (in XLA) VAR_008319
		509	M -> V (in XLA) VAR_006249
		512	L -> P (in XLA) VAR_008961
		512	L -> Q (in XLA) VAR_008962
		518	L -> R (in XLA) VAR_008320
		520	R -> Q (in XLA; severe; prevents activation due to absence of contact between the catalytic loop and the regulatory phosphorylated residue; dbSNP:rs128621202) VAR_006251 dbSNP
		521	D -> G (in XLA) VAR_008321
		521	D -> H (in XLA; severe) VAR_006252
		521	D -> N (in XLA; severe) VAR_006253
		523	A -> E (in XLA) VAR_008322
		525	R -> G (in XLA) VAR_008323
		525	R -> P (in XLA) VAR_006254
		525	R -> Q (in XLA; severe; disturbs ATP-binding; dbSNP:rs128620183) VAR_006255 dbSNP
		526	N -> K (in XLA; dbSNP:rs1569291237) VAR_006256 dbSNP
		535	V -> F (in XLA) VAR_008324
		542	L -> P (in XLA; growth hormone deficiency; dbSNP:rs128621203) VAR_006257 dbSNP
		544	R -> G (in XLA) VAR_008963
		544	R -> K (in XLA) VAR_006258
		559	F -> S (in XLA) VAR_008325
		562	R -> P (in XLA; dbSNP:rs104894770) VAR_006259 dbSNP
		562	R -> W (in XLA; dbSNP:rs128621204) VAR_006260 dbSNP
		563	W -> L (in XLA; dbSNP:rs1555977474) VAR_008326 dbSNP
		567	E -> K (in XLA; severe) VAR_006261
		578	S -> Y (in XLA) VAR_008964
		581	W -> R (in XLA; dbSNP:rs128621205) VAR_006262 dbSNP
		582	A -> V (in XLA) VAR_006263
		583	F -> S (in XLA) VAR_008327
		587	M -> L (in XLA; mild) VAR_006264
		589	E -> D (in XLA) VAR_008328
		589	E -> G (in XLA; moderate; interferes with substrate binding; dbSNP:rs128621206) VAR_006265 dbSNP
		589	E -> K (in XLA) VAR_008965
		592	S -> P (in XLA) VAR_006267
		594	G -> E (in XLA; mild; interferes with substrate binding) VAR_006268
		594	G -> R (in XLA; dbSNP:rs1555977339) VAR_006269 dbSNP
		598	Y -> C (in XLA) VAR_006270
		607	A -> D (in XLA; mild; dbSNP:rs128621208) VAR_006271 dbSNP
		613	G -> D (in XLA; mild; interferes with substrate binding and/or domain interactions; dbSNP:rs128621209) VAR_006272 dbSNP
		619	P -> A (in XLA) VAR_008330
		619	P -> S (in XLA) VAR_006273
		619	P -> T (in XLA) VAR_008331
		622	A -> P (in XLA) VAR_008332
		626	V -> G (in XLA) VAR_008333
		630	M -> I VAR_006274
		630	M -> K (in XLA; dbSNP:rs128621210) VAR_006275 dbSNP
		630	M -> T (in XLA) VAR_008334
		633	C -> Y (in XLA) VAR_006276
		641	R -> C (in XLA) VAR_006277
		641	R -> H (in XLA; severe) VAR_006278
		644	F -> L (in XLA) VAR_008335
		644	F -> S (in XLA) VAR_006279
		647	L -> P (in XLA) VAR_006280
		652	L -> P (in XLA; dbSNP:rs128622212) VAR_006281 dbSNP
		135-171	Btk-type
		408-416	ATP
		260-280	Missing (in XLA; severe) VAR_006226
		5-133	Pleckstrin homology domain IPR001849 PF00169
		141-167	Zinc finger, Btk motif IPR001562 PF00779
		220-266	SH3 domain IPR001452 PF00018
		281-362	SH2 domain IPR000980 PF00017
		402-650	Serine-threonine/tyrosine-protein kinase, catalytic domain IPR001245 PF07714

Experimental structures

Description	Oligo-state	Ligands	Structure	Range
Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihyd…	Heteromer	4×N42;	5j87	385-658
Assess
Ternary complex structure - BTK cIAP compound 15	Heteromer Q13490;	1×ZN; 1×TKY;	6w8i	393-657
Assess
Ternary complex structure - BTK cIAP compound 17	Heteromer Q13490;	1×TL7; 1×ZN;	6w7o	396-656
Assess
Crystal structure of human Btk SH2 domain bound to rF10 repebody	Heteromer		6htf	276-379
Assess
PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT E41K IN COMPLEX WITH INS(1,3,4,5)P4	homo-4-mer	4×ZN; 8×4IP;	1bwn	2-170
Assess
PH DOMAIN FROM BRUTON'S TYROSINE KINASE IN COMPLEX WITH INOSITOL 1,3,4,5-TETRAKISPHOSPHATE	homo-4-mer	4×ZN; 4×4IP;	1b55	2-170
Assess
The structure of human BTK kinase domain in complex with a covalent inhibitor	homo-2-mer	2×GYL;	5xyz	394-656
Assess
CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO …	homo-2-mer	2×6MV;	5jrs	396-656
Assess
Crystal structure of Bruton's tyrosine kinase domain	homo-2-mer		1k2p	397-654
Assess
PH DOMAIN AND BTK MOTIF FROM BRUTON'S TYROSINE KINASE MUTANT R28C	homo-2-mer	2×ZN; 2×NA;	1btk	2-170
Assess
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT FRAGMENT LIGAND	monomer	1×GJD;	6di1	389-659
Assess
BTK1 SOAKED WITH IBRUTINIB-Rev	monomer	1×1E8; 2×DMS;	5p9i	389-659
Assess
CRYSTAL STRUCTURE OF BTK with CNX 774	monomer	1×7G8;	5p9k	389-659
Assess
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGAND	monomer	1×GJG;	6di0	389-659
Assess
Discovery of a potent BTK inhibitor with a novel binding mode using parallel selections with a DNA-…	monomer	1×83P; 3×EDO; 2×PEG;	5u9d	389-659
Assess
BTK1 SOAKED WITH COMPOUND 5, Y551 IS SEQUESTERED	monomer	1×X9M;	7kxm	389-659
Assess
BTK in complex with inhibitor 8-(2,3-dihydro-1H-inden-5-yl)-2-({4-[(2S)-3-(dimethylamino)-2-hydroxy…	monomer	1×KLM; 6×EDO;	6nfh	389-659
Assess
BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059	monomer	1×7GB; 1×DMS;	5p9m	389-659
Assess
Structure of human Bruton's Tyrosine Kinase in complex with Evobrutinib	monomer	1×CL; 1×MZJ;	6omu	389-659
Assess
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITOR	monomer	1×GJ7; 1×DMS;	6di5	389-659
Assess
Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R…	monomer	1×4US; 1×DMS; 2×EDO;	5bq0	389-659
Assess
Bruton's tyrosine kinase (BTK) with GDC-0853	monomer	1×9AJ; 8×EDO; 2×SO4;	5vfi	389-659
Assess
Fragment-Based Discovery of a Small Molecule Reversible Inhibitor of Bruton's Tyrosine Kinase	monomer	2×IMD; 1×IPA; 1×EDO; 1×4L6;	4z3v	389-659
Assess
BTK1 SOAKED WITH COMPOUND 25	monomer	1×X9V; 4×DMS;	7kxp	389-659
Assess
Discovery of affinity-based probes for Btk occupancy assay	monomer	1×KHD;	6n9p	389-659
Assess
Crystal structure of ARQ 531 in complex with the kinase domain of BTK	monomer	1×HRA; 2×IMD; 2×EDO;	6e4f	389-658
Assess
BTK1 SOAKED WITH COMPOUND 30	monomer	2×DMS; 1×X9Y;	7kxq	390-659
Assess
Crystal Structure of Bruton's Tyrosine Kinase bound to a Cinnoline Fragment	monomer	2×IMD; 1×IPA; 1×DMS; 1×4RU;	4zly	389-658
Assess
Crystal Structure of Bruton's Tyrosine Kinase in complex with a substituted Cinnoline	monomer	2×IMD; 1×IPA; 1×DMS; 1×4RV;	4zlz	389-658
Assess
Crystal structure of BTK kinase domain complexed with 2-[4-(2-Diethylamino-ethoxy)-phenylamino]-6-(…	monomer	1×04K;	3pj2	391-659
Assess
Crystal structure of BTK kinase domain complexed with 2-Methyl-5-[(E)-(3-phenyl-acryloyl)amino]-N-(…	monomer	1×04L;	3pj3	391-659
Assess
Crystal structure of BTK kinase domain complexed with 3-(2,6-Dichloro-phenyl)-7-[4-(2-diethylamino-…	monomer	2×LHL;	3pj1	391-659
Assess
Crystal structure of BTK kinase domain complexed with (5-Amino-1-o-tolyl-1H-pyrazol-4-yl)-[3-(1-met…	monomer	1×03C;	3piz	391-659
Assess
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH COVALENT INHIBITOR	monomer	1×GJJ; 1×DMS;	6di9	392-659
Assess
BTK In Complex With Inhibitor	monomer	1×LTJ;	6o8i	391-658
Assess
Crystal structure of BTK kinase domain complexed with 2-Isopropyl-7-(4-methyl-piperazin-1-yl)-4-(5-…	monomer	1×027;	3pix	391-658
Assess
BTK-inhibitor co-structure	monomer	1×5WH; 1×5WE;	5fbo	392-659
Assess
Co-structure of BTK kinase domain with L-005085737 inhibitor	monomer	1×ULV; 1×5WE;	6x3n	392-659
Assess
Bruton's tyrosine kinase in complex with a t-butyl cyanoacrylamide inhibitor	monomer	1×4C9; 9×NA; 2×EDO; 2×SO4; 3×CL;	4yhf	391-658
Assess
BTK in complex with inhibitor N-(3-{[(2,6-dimethylphenyl)methyl]amino}-7-methoxyindeno[1,2-c]pyrazo…	monomer	1×KLP; 2×SO4;	6nfi	392-659
Assess
Crystal structure of BTK kinase domain complexed with R406	monomer	1×585;	3piy	391-658
Assess
Co-crystal structure of BTK kinase domain with Zanubrutinib	monomer	1×BA0; 1×IMD;	6j6m	393-659
Assess
Bruton's tyrosine kinase in complex with compound 5	monomer	2×DMS; 1×RQS;	6vxq	392-658
Assess
Bruton's tyrosine kinase in complex with compound 6	monomer	1×DMS; 1×DTT; 1×S5M;	6w06	393-659
Assess
The 1.6 A crystal structure of human bruton's tyrosine kinase bound to a pyrrolopyrimidine-containi…	monomer	1×B43;	3gen	392-658
Assess
BTK1 SOAKED WITH COMPOUND 5, Y551 IS SEQUESTERED	monomer	1×X9J; 3×DMS;	7kxl	392-658
Assess
Structures of human Bruton's tyrosine kinase in active and inactive conformations suggests a mechan…	monomer	1×1N1;	3k54	392-658
Assess
CRYSTAL STRUCTURE OF BTK IN COMPLEX WITH FRAGMENT LIGAND	monomer	1×GJA;	6di3	393-659
Assess
BTK1 COCRYSTALLIZED WITH IBRUTINIB	monomer	1×8E8;	5p9j	394-659
Assess
BTK1 IN COMPLEX WITH CC 292	monomer	1×7G9;	5p9l	392-657
Assess
Co-structure of BTK kinase domain with L-005298385 inhibitor	monomer	2×UM4; 1×EDO; 1×BTB;	6x3p	394-659
Assess
BTK1 SOAKED WITH COMPOUND 26	monomer	1×X9P; 2×DMS;	7kxn	394-659
Assess
Bruton's tyrosine kinase in complex with compound 1	monomer	1×S9A; 1×DMS;	6w07	393-658
Assess
BTK IN COMPLEX WITH GDC-0834	monomer	1×2VL; 4×EDO; 1×GOL;	5p9f	394-659
Assess
BTK in complex with LOU064, a potent and highly selective covalent inhibitor	monomer	1×NA; 1×N6Z;	6tfp	393-658
Assess
BTK complex with compound 12	monomer	3×SO4; 1×DXM; 1×FPZ; 2×GOL;	6bkw	393-657
Assess
Brutons tyrosine kinase in complex with compound 50.	monomer	1×L9S; 1×EDO;	6nzm	395-659
Assess
Structure of BTK with RN486	monomer	1×7G6;	5p9g	394-658
Assess
Co-structure of BTK kinase domain with L-005191930 inhibitor	monomer	1×ULY; 1×5WE;	6x3o	395-659
Assess
BTK1 SOAKED WITH COMPOUND 24	monomer	1×X9S; 5×DMS;	7kxo	395-659
Assess
Crystal structure of BTK kinase domain complexed with 4-Methanesulfonyl-N-(3-{8-[4-(morpholine-4-ca…	monomer	1×2V1;	4ot6	394-658
Assess
Crystal structure of the human BTK kinase domain	monomer		3p08	394-658
Assess
Bruton's tyrosine kinase (BTK) with pyridazinone compound 23	monomer	2×SO4; 2×GOL; 1×PG0; 1×3YO;	4rx5	394-657
Assess
Bruton's tyrosine kinase (BTK) with pyridazinone compound 9	monomer	2×SO4; 2×GOL; 1×PG0; 1×6XL;	5kup	394-657
Assess
Bruton's tyrosine kinase (BTK) with compound G-744	monomer	2×SO4; 2×GOL; 2×PG0; 1×9B1;	5vgo	394-657
Assess
BTK kinase domain with inhibitor 1	monomer	1×5WF; 1×5WE; 1×CL;	5fbn	395-658
Assess
BTK1 COCRYSTALLIZED WITH RN983	monomer	1×7G7;	5p9h	395-658
Assess
CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-m…	monomer	1×GMQ;	6hrp	396-658
Assess
Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-8-fluoro-2-[2-(hydroxymethy…	monomer	1×3OV; 2×DMS;	4rfz	396-658
Assess
BTK complex with compound 13	monomer	3×SO4; 1×DY4; 1×GOL;	6bln	395-657
Assess
CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 12-(6-tert-butyl-8-fluoro-1-oxo-phthalazin-2-…	monomer	1×GMW;	6hrt	396-658
Assess
Crystal structure of Bruton agammabulinemia tyrosine kinase complexed with BMS-986142 aka (2s)-6-fl…	monomer	1×73T;	5t18	396-658
Assess
Crystal structure of BTK kinase domain complexed with 4-tert-Butyl-N-(3-{8-[4-(4-methyl-piperazine-…	monomer	1×481; 2×DMS;	4ot5	396-658
Assess
Crystal structure of BTK kinase domain complexed with 1-[5-[3-(7-tert-butyl-4-oxo-quinazolin-3-yl)-…	monomer	1×2V2; 2×DMS;	4otq	396-658
Assess
BTK Fluorocyclopropyl amide inhibitor, Compound 25	monomer	1×V1G; 2×SO4;	6xe4	395-657
Assess
CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2815	monomer	2×SO4; 1×BXM;	6aub	395-657
Assess
CRYSTAL STRUCTURE OF BRUTON'S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI2625	monomer	1×GOL; 2×SO4; 1×BXJ;	6aua	394-656
Assess
Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-m…	monomer	1×3OU; 2×DMS;	4rfy	396-658
Assess
BTK complex with compound 7	monomer	3×SO4; 1×DTJ; 1×GOL;	6bik	395-657
Assess
BTK complex with compound 10	monomer	3×SO4; 1×DVJ;	6bke	395-657
Assess
Crystal structure of BTK kinase domain complexed with 6-cyclopropyl-2-[3-[5-[[5-(4-ethylpiperazin-1…	monomer	1×2V3; 2×DMS;	4otr	396-658
Assess
Crystal structure of bruton's tyrosine kinase mutant V555R in complex with dasatinib	monomer	1×1N1;	3oct	394-656
Assess
Crystal structure of BTK kinase domain complexed with N-[2-methyl-3-[4-methyl-6-[4-(4-methylpiperaz…	monomer	1×BNB;	6ep9	396-658
Assess
Crystal structure of BTK kinase domain complexed with 2-[8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-…	monomer	1×3P0;	4rg0	396-658
Assess
BTK complex with compound 11	monomer	4×SO4; 1×DVD;	6bkh	396-657
Assess
Crystal structure of bruton's tyrosine kinase in complex with inhibitor CGI1746	monomer	3×SO4; 1×BME; 1×746;	3ocs	395-656
Assess
BTK in complex with an inhibitor	monomer	1×L0Z;	6s90	395-656
Assess
Crystal structure of the kinase domain of Bruton's Tyrosine kinase with GDC0834	monomer	3×SO4; 1×2VL;	4otf	396-657
Assess
Crystal structure of Bruton agammaglobulinemia tyrosine kinase complexed with BMS-809959 aka 4-tert…	monomer	1×2P5;	4nwm	396-657
Assess
Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R…	monomer	1×4UQ;	5bpy	396-657
Assess
Crystal structure of bruton's tyrosine kinase in complex with inhibitor 2e	monomer	1×9M3;	5zz4	395-655
Assess
The PH domain of Bruton's tyrosine kinase mutant R28C	monomer	1×MG; 1×ZN;	6tt2	2-169
Assess
Crystal Structure of 1-methylindoline-2,3-dione covalently bound to the PH domain of Bruton's tyros…	monomer	1×MG; 3×72V; 1×ZN;	6tse	2-169
Assess
Crystal Structure of 5-chloroindoline-2,3-dione covalently bound to the PH domain of Bruton's tyros…	monomer	1×3IS; 1×ZN; 1×MG;	6yyf	2-169
Assess
Crystal Structure of 5-(trifluoromethoxy)indoline-2,3-dione covalently bound to the PH domain of Br…	monomer	1×Q1B; 1×MG; 1×ZN;	6yyg	2-169
Assess
Crystal Structure of 1,5-dimethylindoline-2,3-dione covalently bound to the PH domain of Bruton's t…	monomer	1×ZN; 1×MG;	6yyk	2-169
Assess
The PH domain of Bruton's tyrosine kinase mutant R28C	monomer	2×NXT; 1×MG; 1×ZN;	6tuh	2-168
Assess
Crystal Structure of 5-bromoindoline-2,3-dione covalently bound to the PH domain of Bruton's tyrosi…	monomer	1×NYQ; 1×ZN; 1×MG;	6tvn	2-168
Assess
Crystal structure of PH domain of Bruton's tyrosine kinase	monomer	1×ZN; 1×4PT;	2z0p	2-168
Assess
Solution Structures of the SH2 domain of Bruton's Tyrosine Kinase	monomer		2ge9	270-387
Assess
SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, MINIMIZED AVERAGE STRUCTURE	monomer		1awx	211-275
Assess
SH3 DOMAIN FROM BRUTON'S TYROSINE KINASE, NMR, 42 STRUCTURES	monomer		1aww	211-275
Assess
NMR Study of the SH3 Domain From Bruton's Tyrosine Kinase, 20 Structures	monomer		1qly	216-273
Assess

Homology models

Oligo-state	QMEAN	Template	Range	Seq id (%)	Ligands
monomer	-1.20	4xi2.1.A	214-657	98.21	1×AU;
Assess
monomer	-2.50	2h8h.1.A	218-656	38.27
Assess
monomer	-1.89	1opl.2.A	275-657	39.82
Assess
monomer	-2.81	1y57.1.A	216-656	38.62
Assess

Homology models built on isoform sequence

Isoform	Oligo-state	Ligands	QMEAN	Template	Range	Seq id (%)
Isoform 2	monomer	1×AU;	-1.22	4xi2.1.A	248-691	98.21
Assess
Isoform 2	monomer		-2.18	4k11.1.A	252-690	38.57
Assess
Isoform 2	monomer		-1.92	1opl.2.A	309-691	39.82
Assess
Isoform 2	monomer		-2.78	1y57.1.A	250-690	38.62
Assess

Q06187 (BTK_HUMAN) Homo sapiens (Human)

Tyrosine-protein kinase BTK UniProtKBInterProSTRINGInteractive Modelling

Homology Model

Model Quality Estimate

Sequence Features

Sequence Alignments

Experimental structures

Homology models

Homology models built on isoform sequence

Background

Resolution

Tyrosine-protein kinase BTK UniProtKB InterPro STRING Interactive Modelling